Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020
November 02 2020 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that the Company
will host a conference call and live audio webcast on Monday,
November 9, 2020, at 4:30 p.m. ET to report third quarter 2020
financial results and provide a corporate update.
To participate in the conference call, please
dial (855) 445-2816 (domestic) or (484) 756-4300 (international)
and refer to conference ID 2192536. A live webcast of the call can
be accessed under “Events & Presentations” in the News &
Investors section of the Company’s website at
www.CaraTherapeutics.com.
An archived webcast recording will be available
on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. In two Phase 3 trials, KORSUVA Injection has
demonstrated statistically significant reductions in itch intensity
and concomitant improvement in quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP). Cara has successfully
completed its Phase 2 trial of Oral KORSUVA for the treatment of
pruritus in patients with CKD and is currently conducting Phase 2
trials of Oral KORSUVA in atopic dermatitis and primary biliary
cholangitis patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.212-362-1200 janhavi.mohite@SternIR.com
MEDIA CONTACT:Annie Starr6 Degrees973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024